PBS dispute could leave MS patients with huge bills for crucial drugs Ocrevus and Kesimpta
A dispute over how Australia prices medicines has sparked fears 10,000 people with multiple sclerosis will be forced…
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite…
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite…
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib,…
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites…
Novartis and US government reach agreement on lowering drug prices in the US
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be…
Progress In Fight Against Malaria, As New Treatment Shows Promise
A child is vaccinated against malaria on September 13, 2019 in Ndhiwa, Homabaya County, Western Kenya during the…
One in four Indians faces silent genetic threat to heart health, shows study
In the Asia Pacific and Middle East region, two in three individuals (66%) skip routine heart tests, while…
AI Tools Are Spreading Medical Scams Online
In this week’s edition of InnovationRx, we look at AI medical scams, using machine learning to derive drugs…
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
President Trump’s tariffs could erode healthcare companies’ profits, but some may perform well regardless. Eli Lilly and Novartis…